ClinicalTrials.gg
CompletedNCT01134393Updated Jan 15, 2014Results posted

TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch

A Phase 3 interventional study of telmisartan/amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 47 sites in 5 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-01-15.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
502
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
25th of 99
502 · median 184
Started
2010
with 5 others
Phase 3
40 of 99
none open now
Registered
40th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 25th largest by enrollment, is one of 6 that started in 2010, is one of 40 in phase 3, and was the 40th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks. In-clinic blood pressures, home blood pressures and safety will be carefully monitored.

Read the detailed description

Study Design:

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide written in accordance with Good Clinical Practice and local legislation
  2. Age 18 years or older
  3. Patients with uncontrolled hypertension as defined SBP > 140 mmHg and SBP > 130 mmHg in patients with diabetes or renal impairment or DBP > 90 mmHg and DBP >80 mmHg in patients with diabetes or renal impairment after at least an 6 weeks of stable treatment with antihypertensive medication defined as treatment with the clinically recommended dose of a single RAAS blocking agent (Angiotensin Converting Enzym inhibition, AII Receptor Blocker and Direct Renin Inhibitor) at entering the trial. Renal impairment is defined as a creatinine >133µmol/l (1.5mg/dl) in male patients and a creatinine >124µmol/l (1.3mg/dl) in female patients or a between 30-60 ml/min

Exclusion criteria

Exclusion criteria:

  1. Pre-menopausal women who are not surgically sterile; or are nursing or pregnant; or are not practising acceptable means of or do not plan to continue using acceptable means of birth control throughout the study and do not agree to submit to pregnancy testing during participation in the trial. Acceptable methods of birth control include the transdermal patch, oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner.
  2. Known or suspected secondary hypertension (e.g., renal artery stenosis or phaeochromocytoma).
  3. Mean in-clinic seated cuff Systolic BP >180 mmHg and SBP >160 mmHg in patients with diabetes or renal impairment or Diastolic BP >110 mmHg and DBP >100 mmHg in patients with diabetes or renal impairment. Renal impairment is defined as a creatinine >133µmol/l (1.5mg/dl) in male patients and a creatinine >124µmol/l (1.3mg/dl) in female patients or a between 30-60 ml/min.
  4. Renal dysfunction as defined by the following laboratory parameters: Serum creatinine >3.0 mg/dl (or >265 ¿mol/L) and/or known creatinine clearance of \<30 ml/min and/or clinical markers of severe renal impairment.
  5. Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant patients or patients with only one kidney.
  6. hypokalaemia or hyperkalaemia (i.e., \<3.5 or >5.5 mEq/L).
  7. Uncorrected sodium or volume depletion.
  8. Primary aldosteronism.
  9. Hereditary fructose intolerance.
  10. Congestive heart failure functional class Congestive Heart Failure III-IV (Refer to Appendix 10.1).
  11. Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the Investigator.
  12. Biliary obstructive disorders (e.g., cholestasis) or hepatic insufficiency (defined as elevated levels of >2x or >2x transaminases values). (Refer to Appendix 10.3)
  13. Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin-II receptor antagonists.
  14. History of drug or alcohol dependency within six months prior to signing the form.
  15. Any drug therapy within one month of signing the informed consent.
  16. Known to any component of the trial drugs (telmisartan or amlodipine).
  17. History of non-compliance or inability to comply with prescribed medications or protocol procedures.
  18. Any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of the trial medication.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
502 participants (actual)

Study arms

  • Experimental
    telmisartan/amlodipine

    start low dose and uptitrate to high dose on the basis of blood pressure goal

    Drug: telmisartan/amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.

    Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.

    Time frame: 12 weeks

Secondary outcomes

  1. BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.

    Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.

    Time frame: 4 and 8 weeks

  2. BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).

    Achieving BP control with HBPM is defined as SBP\<135 mmHg and DBP\<85 mmHg.

    Time frame: Week 12

  3. Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP

    Time frame: weeks 4, 8 and 12

  4. Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate

    Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.

    Time frame: weeks 4, 8 and 12

  5. Change From Baseline Over Time in In-clinic Measured Mean Pulse Pressure

    Time frame: weeks 4, 8 and 12

  6. DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements

    DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

    Time frame: weeks 4, 8 and 12

  7. Percentage of Patients in Blood Pressure Categories Over Time

    BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

    Time frame: weeks 4, 8 and 12

  8. DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements

    DBP control: DBP \<85 mmHg, SBP control: SBP \<135 mmHg, DBP response: DBP \<85 mmHg or a reduction from baseline \>=10 mmHg, SBP response: SBP \<135 mmHg or a reduction from baseline \>= 15 mmHg

    Time frame: weeks 4, 8 and 12

  9. Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time

    Time frame: weeks 4 and 8

07

Results

Posted Jul 4, 2012

Participant flow

Participant flow — Overall Study
MilestoneT80/A5
Started501
Completed449
Not completed52
Withdrew: Adverse event18
Withdrew: Lack of efficacy2
Withdrew: Protocol violation12
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject11
Withdrew: Other6

Outcome measures

PrimaryPercentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.

Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.

Time frame:
12 weeks
Reported as:
Number · Percentage of participants
Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.
Percentage of participantsT80/A5
Percentage of Patients Achieving Blood Pressure (BP) Control After 12 Weeks of Treatment Using In-clinic BP Measurements.67.6 (63.3 to 71.7)
SecondaryBP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.

Achieving BP control is defined as SBP\<140 mmHg and DBP\<90 mmHg.

Time frame:
4 and 8 weeks
Reported as:
Number · Number of participants
BP Control After 4 and 8 Weeks of Treatment Using In-clinic BP Measurements.
Number of participantsT80/A5
Week 4262
Week 8330
SecondaryBP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).

Achieving BP control with HBPM is defined as SBP\<135 mmHg and DBP\<85 mmHg.

Time frame:
Week 12
Reported as:
Number · Number of participants
BP Control (Morning and Evening) After 12 Weeks of Treatment Using Home Blood Pressure Measurement (HBPM).
Number of participantsT80/A5
Morning179
Evening172
SecondaryChange From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP
Time frame:
weeks 4, 8 and 12
Reported as:
Mean · mmHg
Change From Baseline Over Time in In-clinic Measured Mean SBP and Mean DBP
mmHgT80/A5
Change at week 4 SBP (N=485)-13.58 ± 11.95
Change at week 8 SBP (N=487)-16.37 ± 12.34
Change at week 12 SBP (N=487)-16.92 ± 12.24
Change at week 4 DBP (N=485)-8.24 ± 8.77
Change at week 8 DBP (N=487)-10.33 ± 8.88
Change at week 12 DBP (N=487)-10.43 ± 8.83
SecondaryChange From Baseline Over Time in In-clinic Measured Mean Pulse Rate

Pulse pressure was not analysed for this study instead pulse rate was analysed at weeks 4, 8 and 12.

Time frame:
weeks 4, 8 and 12
Reported as:
Mean · bpm
Change From Baseline Over Time in In-clinic Measured Mean Pulse Rate
bpmT80/A5
Change at week 4 (N=482)1.43 ± 9.22
Change at week 8 (N=463)0.32 ± 9.21
Change at week 12 (N=344)0.51 ± 9.25
SecondaryChange From Baseline Over Time in In-clinic Measured Mean Pulse Pressure
Time frame:
weeks 4, 8 and 12

No measurements were reported for this outcome.

SecondaryDBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements

DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

Time frame:
weeks 4, 8 and 12
Reported as:
Number · Number of participants
DBP and SBP Control and Response Rates After 4, 8 and 12 Weeks of Treatment Using In-clinic BP Measurements
Number of participantsT80/A5
Week 4 DBP control313
Week 8 DBP control368
Week 12 DBP control373
Week 4 SBP control247
Week 8 SBP control305
Week 12 SBP control311
Week 4 DBP response329
Week 8 DBP response393
Week 12 DBP response399
Week 4 SBP response337
Week 8 SBP response388
Week 12 SBP response393
SecondaryPercentage of Patients in Blood Pressure Categories Over Time

BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

Time frame:
weeks 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Patients in Blood Pressure Categories Over Time
Percentage of participantsT80/A5
BP optimal at week 4 (N=482)4.1
BP normal at week 4 (N=482)19.7
BP high-normal at week 4 (N=482)30.5
Grade 1 hypertension at week 4 (N=482)39.0
Grade 2 hypertension at week 4 (N=482)6.2
Grade 3 hypertension at week 4 (N=482)0.4
BP optimal at week 8 (N=487)5.5
BP normal at week 8 (N=487)22.2
BP high-normal at week 8 (N=487)40.0
Grade 1 hypertension at week 8 (N=487)27.7
Grade 2 hypertension at week 8 (N=487)4.3
Grade 3 hypertension at week 8 (N=487)0.2
BP optimal at week 12 (N=487)4.5
BP normal at week 12 (N=487)28.5
BP high-normal at week 12 (N=487)35.5
Grade 1 hypertension at week 12 (N=487)27.1
Grade 2 hypertension at week 12 (N=487)4.1
Grade 3 hypertension at week 12 (N=487)0.2
SecondaryDBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements

DBP control: DBP \<85 mmHg, SBP control: SBP \<135 mmHg, DBP response: DBP \<85 mmHg or a reduction from baseline \>=10 mmHg, SBP response: SBP \<135 mmHg or a reduction from baseline \>= 15 mmHg

Time frame:
weeks 4, 8 and 12
Reported as:
Number · Number of participants
DBP and SBP Control and Response Rates Morning and Evening Over Time HBPM Measurements
Number of participantsT80/A5
DBP control morning at week 4256
DBP control morning at week 8242
DBP control morning at week 12252
DBP control evening at week 4272
DBP control evening at week 8247
DBP control evening at week 12263
SBP control morning at week 4204
SBP control morning at week 8198
SBP control morning at week 12206
SBP control evening at week 4204
SBP control evening at week 8183
SBP control evening at week 12190
DBP response morning at week 4 (N=354)256
DBP response morning at week 8 (N=354)242
DBP response morning at week 12 (N=354)252
DBP response evening at week 4 (N=354)272
DBP response evening at week 8 (N=354)247
DBP response evening at week 12 (N=354)263
SBP response morning at week 4 (N=299)204
SBP response morning at week 8 (N=299)198
SBP response morning at week 12 (N=299)206
SBP response evening at week 4 (N=299)204
SBP response evening at week 8 (N=299)183
SBP response evening at week 12 (N=299)190
SecondaryFrequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time
Time frame:
weeks 4 and 8
Reported as:
Number · Number of participants
Frequency of Patients Requiring Up-titration to Telmisartan 80mg Plus Amlodipine 10mg Combination (T80/A10) to Achieve Blood Pressure Control Over Time
Number of participantsT80/A5
Week 4 (n=482)186
Week 8 (n=284)46

Adverse events

Collected over 12 weeks: From drug administration until end of treatment plus one day.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T80/A5—1/501 (0.2%)26/501 (5.2%)
T80/A10—1/232 (0.4%)41/232 (17.7%)
Most frequent serious events
Most frequent serious events
EventT80/A5T80/A10
Femur fractureInjury, poisoning and procedural complications0/5011/232
Fibula fractureInjury, poisoning and procedural complications0/5011/232
Upper limb fractureInjury, poisoning and procedural complications0/5011/232
Duodenal ulcerGastrointestinal disorders1/5010/232
Most frequent other events
Most frequent other events
EventT80/A5T80/A10
Oedema peripheralGeneral disorders26/50141/232

Baseline characteristics

Age, Continuous
Age, Continuous(Years)T80/A5
Mean58.0 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)T80/A5
Female207
Male287
Systolic Blood Pressure (SBP) at time of baseline
Systolic Blood Pressure (SBP) at time of baseline(mmHg)T80/A5
Mean151.4 ± 10.2
Diastolic Blood Pressure (DBP) at time of baseline
Diastolic Blood Pressure (DBP) at time of baseline(mmHg)T80/A5
Mean91.8 ± 8.8
08

Study locations

47 sites
  • 1235.33.49010 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1235.33.49002 Boehringer Ingelheim Investigational Site
    Frankfurt, Germany
  • 1235.33.49007 Boehringer Ingelheim Investigational Site
    Haag, Germany
  • 1235.33.49003 Boehringer Ingelheim Investigational Site
    Heidelberg, Germany
  • 1235.33.49005 Boehringer Ingelheim Investigational Site
    Künzing, Germany
  • 1235.33.49008 Boehringer Ingelheim Investigational Site
    Nürnberg, Germany
  • 1235.33.49009 Boehringer Ingelheim Investigational Site
    Rednitzhembach, Germany
  • 1235.33.49006 Boehringer Ingelheim Investigational Site
    Rodgau-Dudenhofen, Germany
  • 1235.33.49004 Boehringer Ingelheim Investigational Site
    Unterschneidheim, Germany
  • 1235.33.49001 Boehringer Ingelheim Investigational Site
    Westerkappeln, Germany
  • 1235.33.39009 Boehringer Ingelheim Investigational Site
    Arezzo, Italy
  • 1235.33.39002 Boehringer Ingelheim Investigational Site
    Bologna, Italy
  • 1235.33.39004 Boehringer Ingelheim Investigational Site
    Ferrara, Italy
  • 1235.33.39006 Boehringer Ingelheim Investigational Site
    L'Aquila, Italy
  • 1235.33.39007 Boehringer Ingelheim Investigational Site
    Napoli, Italy
  • 1235.33.39001 Boehringer Ingelheim Investigational Site
    Pisa, Italy
  • 1235.33.39008 Boehringer Ingelheim Investigational Site
    Roma, Italy
  • 1235.33.39005 Boehringer Ingelheim Investigational Site
    Stradella (PV), Italy
  • 1235.33.52004 Boehringer Ingelheim Investigational Site
    Aguascalientes, Mexico
  • 1235.33.52002 Boehringer Ingelheim Investigational Site
    Durango, Mexico
  • 1235.33.52001 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1235.33.52003 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1235.33.52007 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1235.33.52006 Boehringer Ingelheim Investigational Site
    Mexico, Mexico
  • 1235.33.52009 Boehringer Ingelheim Investigational Site
    Mexico, Mexico
  • 1235.33.52008 Boehringer Ingelheim Investigational Site
    Monterrey, Mexico
  • 1235.33.31007 Boehringer Ingelheim Investigational Site
    's Hertogenbosch, Netherlands
  • 1235.33.31009 Boehringer Ingelheim Investigational Site
    Almere, Netherlands
  • 1235.33.31005 Boehringer Ingelheim Investigational Site
    Beek en Donk, Netherlands
  • 1235.33.31002 Boehringer Ingelheim Investigational Site
    Beerzerveld, Netherlands
  • 1235.33.31008 Boehringer Ingelheim Investigational Site
    Ermelo, Netherlands
  • 1235.33.31006 Boehringer Ingelheim Investigational Site
    Lichtenvoorde, Netherlands
  • 1235.33.31001 Boehringer Ingelheim Investigational Site
    Musselkanaal, Netherlands
  • 1235.33.31004 Boehringer Ingelheim Investigational Site
    Nijverdal, Netherlands
  • 1235.33.31003 Boehringer Ingelheim Investigational Site
    Wildervank, Netherlands
  • 1235.33.48005 Boehringer Ingelheim Investigational Site
    Chorzow, Poland
  • 1235.33.48002 Boehringer Ingelheim Investigational Site
    Czestochowa, Poland
  • 1235.33.48003 Boehringer Ingelheim Investigational Site
    Czestochowa, Poland
  • 1235.33.48010 Boehringer Ingelheim Investigational Site
    Dabrowa Gornicza, Poland
  • 1235.33.48006 Boehringer Ingelheim Investigational Site
    Grodzisk Mazowiecki, Poland
  • 1235.33.48013 Boehringer Ingelheim Investigational Site
    Oswiecim, Poland
  • 1235.33.48008 Boehringer Ingelheim Investigational Site
    Piotrkow Trybunalski, Poland
  • 1235.33.48004 Boehringer Ingelheim Investigational Site
    Poznan, Poland
  • 1235.33.48001 Boehringer Ingelheim Investigational Site
    Tychy, Poland
  • 1235.33.48009 Boehringer Ingelheim Investigational Site
    Tychy, Poland
  • 1235.33.48011 Boehringer Ingelheim Investigational Site
    Warszawa, Poland
  • 1235.33.48007 Boehringer Ingelheim Investigational Site
    Wroclaw, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2010
First posted
Jun 2, 2010
Start
May 2010
Primary completionActual
May 2011
Results first posted
Jul 4, 2012
Last update
Jan 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01134393
Responsible party
Sponsor
First posted
Jun 2, 2010
Start date
May 2010
Primary completion
May 2011
Results posted
Jul 4, 2012
Last update
Jan 15, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine

Start the discussion